

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Emerging positive high-level results from the ongoing Phase III MARIPOSA trial of first-line amivantamab in combination with lazertinib versus osimertinib for patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) revealed which of the following outcomes with amivantamab in combination with lazertinib?**
 - a. Statistically significant improvement in progression-free survival (PFS) but no improvement in overall survival (OS)
 - b. Statistically significant improvement in PFS with a trend toward OS improvement
 - c. Statistically significant improvements in both PFS and OS**
- 2. The Phase III HERTHENA-Lung02 trial comparing patritumab deruxtecan to doublet chemotherapy for patients with advanced NSCLC with an EGFR mutation and disease progression on a third-generation EGFR tyrosine kinase inhibitor reported which of the following outcomes with patritumab deruxtecan?**
 - a. Significantly improved PFS**
 - b. Significantly improved OS
 - c. Both a and b
 - d. Neither a nor b
- 3. Second interim analysis from the ongoing Phase III MARIPOSA-2 trial of amivantamab with chemotherapy versus chemotherapy alone for EGFR-mutated advanced NSCLC after disease progression on osimertinib revealed which of the following outcomes with the amivantamab combination?**
 - a. Statistically significant improvement in PFS but no improvement in OS
 - b. Statistically significant improvement in PFS with a trend toward OS improvement**
 - c. Statistically significant improvements in both PFS and OS
- 4. Which of the following is being compared to pemetrexed in combination with carboplatin for patients with EGFR-mutated advanced nonsquamous NSCLC who have experienced disease progression on prior EGFR tyrosine kinase inhibitors in the ongoing Phase III TroFuse-009 trial?**
 - a. Datopotamab deruxtecan
 - b. Patritumab deruxtecan
 - c. Sacituzumab tirumotecan**
 - d. Telisotuzumab vedotin
- 5. The novel irreversible EGFR inhibitor zipalertinib inhibits which forms of the EGFR protein?**
 - a. Wild-type EGFR
 - b. EGFR harboring classical mutations (exon 19 del and exon 21 L858R)
 - c. EGFR harboring exon 20 insertion mutations**
 - d. Both a and c
 - e. Both b and c